Abbott Laboratories (ABT) Cash & Equivalents (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Cash & Equivalents data on file, last reported at $6.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 4.15% year-over-year to $6.8 billion; the trailing twelve-month figure through Mar 2026 stood at $6.8 billion (up 4.15% YoY), and the FY2025 full-year result was $8.5 billion, up 11.9% from the prior year.
• Cash & Equivalents eased to $6.8 billion in Q1 2026, from $8.5 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $9.9 billion in Q4 2022 to a low of $6.3 billion in Q1 2024.
• A 5-year average of $7.7 billion and a median of $7.6 billion in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents rose 19.36% in 2023 and sank 31.4% in 2024, its largest moves.
• Tracing ABT's Cash & Equivalents over 5 years: stood at $9.9 billion in 2022, then plunged by 30.22% to $6.9 billion in 2023, then advanced by 10.44% to $7.6 billion in 2024, then increased by 11.9% to $8.5 billion in 2025, then declined by 20.17% to $6.8 billion in 2026.
• Business Quant data shows ABT's Cash & Equivalents at $6.8 billion in Q1 2026, $8.5 billion in Q4 2025, and $7.5 billion in Q3 2025.